Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2014-001353-16
    Sponsor's Protocol Code Number:BAY63-2521/16277
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2015-05-14
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2014-001353-16
    A.3Full title of the trial
    A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
    Studio di Fase II randomizzato, in doppio cieco, controllato verso placebo, per valutare l’efficacia e la sicurezza di riociguat in pazienti affetti da sclerosi sistemica cutanea diffusa (dcSSc)
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Effectiveness and safety of riociguat in patients with sclerosis of the skin
    Riociguat nella sclerosi sistemica cutanea diffusa (dcSSc)
    A.3.2Name or abbreviated title of the trial where available
    Effectiveness and safety of riociguat in patients with sclerosis of the skin
    Riociguat nella sclerosi sistemica cutanea diffusa (dcSSc)
    A.4.1Sponsor's protocol code numberBAY63-2521/16277
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorBayer HealthCare AG
    B.1.3.4CountryGermany
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportBayer HealthCare AG
    B.4.2CountryGermany
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationBayer HealthCare AG
    B.5.2Functional name of contact pointClinical Trials Contact
    B.5.3 Address:
    B.5.3.1Street AddressCTP Team / Ref: "EU CTR" /Bayer Pharma AG
    B.5.3.2Town/ cityBerlin
    B.5.3.3Post code13342
    B.5.3.4CountryGermany
    B.5.6E-mailclinical-trials-contact@bayerhealthcare.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name ADEMPAS - 1 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PP/ALU) - 42 COMPRESSE
    D.2.1.1.2Name of the Marketing Authorisation holderBayer Pharma AG
    D.2.1.2Country which granted the Marketing AuthorisationItaly
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEMA/OD/044/14
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNRiociguat
    D.3.9.4EV Substance CodeSUB32880
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name ADEMPAS - 1 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PP/ALU) - 42 COMPRESSE
    D.2.1.1.2Name of the Marketing Authorisation holderBayer Pharma AG
    D.2.1.2Country which granted the Marketing AuthorisationItaly
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEMA/OD/044/14
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNRiociguat
    D.3.9.4EV Substance CodeSUB32880
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name ADEMPAS - 1,5 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PP/ALU) - 42 COMPRESSE
    D.2.1.1.2Name of the Marketing Authorisation holderBayer Pharma AG
    D.2.1.2Country which granted the Marketing AuthorisationItaly
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEMA/OD/044/14
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNRiociguat
    D.3.9.4EV Substance CodeSUB32880
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 4
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name ADEMPAS - 2 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PP/ALU) - 42 COMPRESSE
    D.2.1.1.2Name of the Marketing Authorisation holderBayer Pharma AG
    D.2.1.2Country which granted the Marketing AuthorisationItaly
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEMA/OD/044/14
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNRiociguat
    D.3.9.4EV Substance CodeSUB32880
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 5
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name ADEMPAS - 2,5 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PP/ALU) - 42 COMPRESSE
    D.2.1.1.2Name of the Marketing Authorisation holderBayer Pharma AG
    D.2.1.2Country which granted the Marketing AuthorisationItaly
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEMA/OD/044/14
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNRiociguat
    D.3.9.4EV Substance CodeSUB32880
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    diffuse cutaneous systemic sclerosis (dcSSc)
    Sclerosi sistemica (SSc)
    E.1.1.1Medical condition in easily understood language
    diffuse sclerosis of the skin
    Diffuse cutaneous systemic sclerosis (dcSSc)
    E.1.1.2Therapeutic area Diseases [C] - Skin and Connective Tissue Diseases [C17]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 18.0
    E.1.2Level LLT
    E.1.2Classification code 10012977
    E.1.2Term Diffuse systemic sclerosis
    E.1.2System Organ Class 100000004859
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective of this study is to assess the efficacy of riociguat administered 3 times a day (TID) as compared with placebo in terms of change in the mRSS from baseline to Week 52.
    Valutare l’efficacia di riociguat somministrato 3 volte al giorno (TID) rispetto al placebo in termini di variazione della mRSS dal basale alla 52a settimana
    E.2.2Secondary objectives of the trial
    The secondary objectives of this study are to assess the efficacy of treatment with riociguat administered TID as compared with placebo in terms of:
    o mRSS progression rate (defined as increase in mRSS by > 5 units and ≥ 25% from baseline) and mRSS regression rate (defined as decrease in mRSS by > 5 units and ≥ 25% from baseline)
    o Patient’s and physician’s global assessment
    o HRQoL using Short Form 36 (SF-36) and the Scleroderma Health Assessment Questionnaire (SHAQ)
    o Digital ulcer net burden (defined as total number of ulcers at time point minus number of ulcers at baseline) and proportion of patients who do not develop new ulcers
    o Change in FVC (forced vital capacity) % predicted and percent DLCO (carbon monoxide diffusing capacity) % predicted
    o Combined Response Index for Systemic Sclerosis (CRISS)
    o Need for Escape Therapy
    • Efficacia:
    Tasso di progressione della mRSS (definito come l’aumento della mRSS di > 5 unità e di ≥ 25% dal basale) e tasso di regressione della mRSS (definito come la diminuzione della mRSS di > 5 unità e ≥ 25% dal basale)
    Valutazione globale da parte del soggetto e del medico
    HRQoL usando il questionario “Short Form 36” (SF-36) e lo “Scleroderma Health Assessment Questionnaire” (SHAQ)
    Carico netto di ulcere digitali (definito come il numero totale delle ulcere in quel momento meno il numero delle ulcere al basale) e la percentuale di pazienti che non sviluppano nuove ulcere
    o Variazione della FVC (“Forced Vital Capacity”) % prevista e DLCO (capacità di diffusione del monossido di carbonio) % prevista
    “Combined Response Index per Systemic Sclerosis” (CRISS)
    Necessità di una terapia di salvataggio
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1.Written informed consent
    2. Men or women aged 18 years and older
    3. Systemic sclerosis, as defined by ACR/EULAR 2013 criteria
    4. dcSSc according to the LeRoy criteria
    5. Disease duration of ≤ 18 months (defined as time from the first non−Raynaud’s phenomenon manifestation)
    6. ≥ 10 and ≤ 22 mRSS units at the screening visit
    7. FVC ≥ 45% of predicted at screening
    8. DLCO ≥ 40% of predicted (hemoglobin-corrected) at screening
    9. Negative serum pregnancy test in a woman of childbearing potential at the screening visit
    10. Women of childbearing potential must agree to use adequate contraception when sexually active. “Adequate contraception” is defined as any combination of at least 2 effective methods of birth control, of which at least 1 is a physical barrier (e.g. condom with hormonal contraception like implants or combined oral contraceptives, condom with intrauterine devices). This applies since signing of the informed consent form until 30 (+5) days after the last study drug administration.
    1. Consenso informato scritto
    2. Uomini o donne di 18 anni e più
    3. Sclerosi sistemica, definita dai criteri ACR/EULAR 2013
    4. dcSSc secondo i criteri di LeRoy
    5. Durata della malattia ≤ 18 mesi (definita come il tempo che intercorre fra la prima manifestazione del fenomeno non di Raynaud)
    6. ≥ 10 e ≤ 22 unità mRSS alla visita di Screening
    7. FVC ≥ 45% del previsto allo screening
    8. DLCO ≥ 40% del previsto (corretta per l’emoglobina) allo screening
    9. Test di gravidanza sul siero negativo in una donna in età fertile alla visita di screening
    10. Le donne in età fertile devono accettare di usare un’adeguata contraccezione se sono sessualmente attive. “Un’adeguata contraccezione” è definita come un insieme di almeno 2 metodi efficaci di controllo delle nascite, di cui almeno 1 è una barriera fisica (ad esempio un preservativo con contraccezione ormonale o impianti o contraccettivi orali di associazione, un preservativo con uno IUD (dispositivo intra-uterino). Ciò vale a partire dalla firma del modulo di consenso informato fino a 30 (+5) giorni dopo l’ultima somministrazione del farmaco in studio.
    11. Capacità di adeguarsi allo schema delle visite in ospedale ed ai procedimenti correlati allo studio
    E.4Principal exclusion criteria
    1. Limited cutaneous SSc at screening
    2. Major surgery (including joint surgery) within 8 weeks prior to
    screening
    3. Hepatic insufficiency classified as Child-Pugh C
    • Patients with isolated AST or ALT >3xULN or bilirubin >2xULN can be
    included in the trial under the condition of additional monitoring during
    the trial
    4. Estimated glomerular filtration rate (eGFR) < 15 mL/min/1.73m2
    (Modification of Diet in Renal Disease formula) or on dialysis at the
    screening visit. Patients entering the trial with eGFR 15-29
    mL/min/1.73m2 will be undergo additional monitoring of renal function
    - Because the MDRD formula is thought to cause significant bias for
    Japanese patients, the equation for Japanese patients is: 194 x serum
    creatinine (mg/dL) -1.094 x Age -0.287 x 0.739 (if female).
    5. Any prior history of renal crisis
    6. Sitting SBP < 95 mmHg at the screening visit
    7. Sitting heart rate < 50 beats per minute (BPM) at the screening visit
    8. Left ventricular ejection fraction < 40% prior to screening
    9. Diagnosed PAH as determined by right heart catheterization
    10. Pulmonary disease with FVC < 45% of predicted or DLCO
    (hemoglobin-corrected) < 40% of predicted at screening
    11. Active state of hemoptysis or pulmonary hemorrhage, including
    those events managed by bronchial artery embolization
    12. Not permitted prior and concomitant medication (updated)
    13. pregnant or breast feeding women
    14. Women of childbearing potential not willing to use adequate
    contraception and not willing to agree to 4-weekly pregnancy testing
    from Visit 1 (first administration of study drug) onwards until 30 (+5)
    days after last study drug intake.
    1. Anamnesi medica e chirurgica
    • SSc cutanea limitata allo screening
    • Interventi di grande chirurgia (compresi gli interventi chirurgici sulle articolazioni) entro 8 settimane prima dello screening
    • I soggetti con anamnesi di tumori maligni negli ultimi 5 anni diversi dai tumori delle cellule cutanee non melanoma guariti mediante resezione locale o carcinoma in situ
    • Nota ipersensibilità al farmaco in studio (principio attivo o eccipienti)
    2. Criteri relativi al fegato
    • Insufficienza epatica classificata come Child-Pugh C (vedere l’Appendice 14.1 per la tabella di classificazione)
    3. Criteri relativi al rene
    • Filtrazione glomerulare stimata (eGFR) < 15 mL/min/1,73m2 (MDRD = formula della modifica della dieta nella malattia renale) o in dialisi alla visita di screening
    o Poiché si ritiene che l’utilizzo della formula MDRD generi bias significativi nei pazienti giapponesi, l’equazione per i pazienti giapponesi è:
    194 x creatininemia (mg/dL) -1,094 x l’età -0,287 x 0,739 (se femmina).
    • Evidenza di precedenti crisi renali (vedere l’Appendice 14.2 per la definizione)
    4. Criteri cardiovascolari
    • SBP in posizione seduta <95 mmHg alla visita di screening
    • Frequenza cardiaca in posizione seduta <50 battiti al minuto (BPM) alla visita di screening
    • Frazione di eiezione dal ventricolo sinistro < 40% prima dello screening
    5. Criteri relativi al polmone
    • Ipertensione arteriosa polmonare (PAH) diagnosticata come risulta dal cateterismo del cuore destro
    • Malattia polmonare con FVC <45% del previsto o DLCO (corretta per l’emoglobina) <40% del previsto allo screening
    • Stato attivo di emottisi od emorragia polmonare, compresi gli eventi trattati mediante embolizzazione dell’arteria bronchiale
    • Eventuale anamnesi di embolizzazione dell’arteria bronchiale o massiva emottisi entro 3 mesi prima dello screening. (L’emottisi massiva è definita come un’emorragia acuta >240 mL nel corso di 24 ore o un’emorragia ricorrente >100 mL/giorno di seguito)
    6. Esami di laboratorio
    • I soggetti con: emoglobina <9.0 g/dL, conta leucocitaria (WBC) <3000/mm3 (<3 × 109/L), conta piastrinica <100,000/mm3 (<3 × 109/L)
    7. Terapia precedente e concomitante
    • Impiego concomitante di nitrati o donatori di NO (ad esempio nitrato di amile) in qualsiasi forma, compresi i preparati per uso locale; gli inibitori della fosfodiesterasi (PDE) 5 (PDE5) (come sildenafil, tadalafil, vardenafil) ed inibitori aspecifici della PDE (teofillina, dipiridamolo)
    • Terapia concomitante con analoghi della prostaciclina. Sono consentiti il beraprost orale per il trattamento delle ulcere digitali / fenomeno di Raynaud e la terapia a breve termine / intermittente fino a 21 giorni con analoghi della prostaciclina per via endovenosa per le lesioni digitali /intravascolari
    • Trattamento con metotrexato, ciclofosfamide, idrossiclorochina, ciclosporina A, azatioprina, micofenolato mofetile, rapamicina, colchicina, D penicillamina o immunoglobulina per via endovenosa netro 4 settimane prima della visita di screening
    • Trattamento con etanercept entro 2 settimane; infliximab, leflunomide, certolizumab, golimumab, adalimumab, abatacept o tocilizumab entro 8 settimane; o anakinra entro una settimana prima della visita di screening
    • Precedente trattamento con clorambucil, trapianto di midollo osseo od irradiazione linfoide totale
    • Trattamento con rituximab od altri anticorpi anti-CD20 negli ultimi 6 mesi prima dello screening
    8. Altri
    • Donne incinte o che allattano al seno
    • Donne in età fertile che non desiderino usare un’adeguata contraccezione (come è definito nel paragrafo sui criteri di inclusione citato prima) e che non vogliano accettare il test di gravidanza ogni 4 settimane dalla Visita 1 (prima somministrazione del farmaco in studio) in avanti fino a 30 (+5) giorni dopo l’ultima assunzione del farmaco in studio.
    • Qualsiasi altra situazione o terapia che renda il soggetto inadatto per questo studio e non consenta la partecipazione per l’intero periodo programmato dello studio
    • Precedente assegnazione al trattamento durante questo studio
    • Partecipazione in un altro studio clinico con un farmaco sperimentale o un dispositivo medico entro 30 giorni prima della randomizzazione (studi clinici di fase IIII)
    E.5 End points
    E.5.1Primary end point(s)
    Change in mRSS from baseline to Week 52
    Variazione nella mRSS dal basale fino alla Settimana 52
    E.5.1.1Timepoint(s) of evaluation of this end point
    week 52
    Settimana 52
    E.5.2Secondary end point(s)
    • mRSS progression rate (defined as increase in mRSS by > 5 units and > 25% from baseline) and mRSS regression rate (defined as decrease in mRSS by > 5 units and > 25% from baseline)
    • Patient’s and physician’s global assessment
    • HRQoL using SF-36 and the SHAQ
    • Digital ulcer net burden (defined as total number of ulcers at time point minus number of ulcers at baseline) and proportion of patients who do not develop new ulcers
    • Change in FVC (forced vital capacity) % predicted and DLCO (carbon monoxide diffusing capacity) % predicted
    • Combined Response Index for Systemic Sclerosis (CRISS), consisting of five variables: mRSS, FVC % predicted, physician and patient global assessments, and HAQ-DI score (from SHAQ patient reported outcome)
    • Need for Escape Therapy
    mRSS • Test della funzionalità polmonare • PRO / HRQoL • Peggioramento della malattia degli organi terminali (cardiaca, renale, polmonare, ischemia gastrointestinale e digitale)
    E.5.2.1Timepoint(s) of evaluation of this end point
    week 52
    Settimana 52
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Information not present in EudraCT
    E.8.2.2Placebo Yes
    E.8.2.3Other Information not present in EudraCT
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned6
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA40
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Belgium
    Canada
    Czech Republic
    France
    Germany
    Hungary
    Italy
    Japan
    Netherlands
    Spain
    Switzerland
    Turkey
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years7
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years7
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 85
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 45
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state15
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 80
    F.4.2.2In the whole clinical trial 130
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    After end of main placebo-controlled part of the study, all patients who complete Visit 12 (Week 52) will be given the option to participate in a LTE phase. The LTE phase will continue up to 6 years after the Last Patient Last Visit in the main treatment phase. Subsequent treatment should be discussed between the subject and his/her doctor during the final visit at the end of the extension phase. It is expected that the subject will receive standard treatment at the discretion of the physician.
    Dopo la fine della fase principale controllata con placebo, tutti i Pazienti che avranno completato la Visita 12 (Week 52) potranno partecipare in una fase Long Term Extension, che proseguirà fino a 6 anni dopo la LPLV della fase di trattamento principale. Trattamenti successivi dovranno essere concordati tra Paziente e Specialista durante la visita finale della fase di estensione
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2014-12-22
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2015-01-19
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2019-03-28
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 00:43:52 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA